The new guidance is at the low end of previous guidance of $2B-$2.3B.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVAX:
- Novavax (NASDAQ:NVAX) Posts Mixed Q3 Results, Revises Outlook Lower
- Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights
- Novavax options imply 18.2% move in share price post-earnings
- Novavax Earnings Are Coming; Here’s What Matters
- Novavax says data show no benefit for bivalent vaccine compared to BA.1 vaccine
